Land: Singapore
Språk: engelsk
Kilde: HSA (Health Sciences Authority)
TRIAMCINOLONE ACETONIDE
YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
H02AB08
10 mg/ml
INJECTION
TRIAMCINOLONE ACETONIDE 10 mg/ml
INTRAMUSCULAR, INTRADERMAL
Prescription Only
YUNG SHIN PHARMACEUTICAL IND CO LTD
ACTIVE
1991-12-03
Shincort Injection provides a synthetic corticosteroid, structurally related to dexamethasone, with marked anti-inflammatory action. It is primarily glucocorticoid in properties, possessing minimal sodium and water retention when used in therapeutic dosage. INGREDIENT: Each mL of sterile aqueous suspension contains: Triamcinolone Acetonide ........................................................................................................ 10mg ACTIONS: Naturally ocurring glucocorticoids, which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. INDICATIONS: Rheumatic disorders: rheumatoid arthritis, osteoarthritis, synovitis. Allergic states: bronchial asthma, allergic rhinitis, allergic dermatitis. Collagen diseases. Dermatologic diseases. Severe acute and chronic allergic and inflammatory opthalmic diseases. DOSAGE AND ADMINISTRATION: Intramuscular administration. For adults and children over 12 years of age, the suggested initial dose is 60 mg, injected deeply into the gluteal muscle. Dosage is usually adjusted within the range of 40 mg to 80 mg. For children from 6 to 12 years of age, the suggested initial dose is 40 mg, although dosage depends more on the severity of symptoms than on age or weight. For intra-articular or intrabursal administration and for injection into tendon sheaths may vary from 2.5 mg to 5 mg for smaller joints, and from 5 mg to 15 mg for larger joints depending on the specific disease entity being treated. Single injections into several joints for multiple locus involvement, up to a total of 20 mg or more, have been given without incident. For intradermal administration, the initial dose of triamcinolone acetonide will vary depending upon the specific disease entity being treate Les hele dokumentet